A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model [Corrigendum]
Klapproth AP, Shevtsov M, Stangl S, Li WB, Multhoff G. Int J Nanomedicine. 2020;15:4677–4689.
The authors have advised the author and affiliation list on page 4677 is incorrect. The correct author list and affiliations
are as follows.
Alexander P Klapproth1,2,*
Thomas J Carter8
Wei Bo Li2
1Center for Translational Cancer Research Technische Universität München (TranslaTUM), Klinikum Rechts Der Isar, Munich, Germany; 2Institute of Radiation Medicine, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich, Germany; 3Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia; 4Department of Biotechnology, First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia; 5Almazov National Medical Research Centre, Russian Polenov Neurosurgical Institute, St. Petersburg, Russia; 6National Center for Neurosurgery, Nur-Sultan, Kazakhstan; 7Department of Biomedical Cell Technologies, Far Eastern Federal University, Vladivostok,
Russia; 8UCL Cancer Institute, University College London, London, UK
*These authors contributed equally to this work
Page 4682, Intravenously Injected SPIONs section, the text “To further validate the model, two datasets from mice with intravenously injected SPIONs were analyzed” should read “To further validate the model, two previously published supplementary datasets from mice with intravenously injected SPIONs were analyzed”.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.